Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The gut hormone fragment peptide YY3-36 (PYY) reduces appetite and food intake when infused into subjects of normal weight. In common with the adipocyte hormone leptin, PYY reduces food intake by modulating appetite circuits in the hypothalamus. However, in obesity there is a marked resistance to the action of leptin, which greatly limits its therapeutic effectiveness. We investigated whether obese subjects were also resistant to the anorectic effects of PYY. METHODS: We compared the effects of PYY infusion on appetite and food intake in 12 obese and 12 lean subjects in a double-blind, placebo-controlled, crossover study. The plasma levels of PYY, ghrelin, leptin, and insulin were also determined. RESULTS: Caloric intake during a buffet lunch offered two hours after the infusion of PYY was decreased by 30 percent in the obese subjects (P<0.001) and 31 percent in the lean subjects (P<0.001). PYY infusion also caused a significant decrease in the cumulative 24-hour caloric intake in both obese and lean subjects. PYY infusion reduced plasma levels of the appetite-stimulatory hormone ghrelin. Endogenous fasting and postprandial levels of PYY were significantly lower in obese subjects (the mean [+/-SE] fasting PYY levels were 10.2+/-0.7 pmol per liter in the obese group and 16.9+/-0.8 pmol per liter in the lean group, P<0.001). Furthermore, the fasting PYY levels correlated negatively with the body-mass index (r = -0.84, P<0.001). CONCLUSIONS: We found that obese subjects were not resistant to the anorectic effects of PYY. Endogenous PYY levels were low in the obese subjects, suggesting that PYY deficiency may contribute to the pathogenesis of obesity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Studies with PYY agonists administered intravenously have shown reduction in food intake with increased satiety [92, 93], however, a nasal PYY agonist showed minimal efficacy with poor tolerability [94].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [93]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“On the other hand, GLP-1 RA can reduce epicardial fat and semaglutide 2.4 mg have shown to improve physical function and symptoms in people with HFpEF [93].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [93]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Central nervous system control of food intake
Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Ghrelin induces adiposity in rodents
Tschöp, M., Smiley, D. L., & Heiman, M. L. (2000) · Nature · doi:10.1038/35038090 · Cited by 3,949 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
The Eating Attitudes Test: an index of the symptoms of anorexia nervosa
Garner, D. M., & Garfinkel, P. E. (1979) · Psychological Medicine · doi:10.1017/s0033291700030762 · Cited by 3,543 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans
Cummings, D. E., Purnell, J. Q., Frayo, R. S., Schmidova, K., Wisse, B. E., & Weigle, D. S. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1714 · Cited by 2,940 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Ghrelin enhances appetite and increases food intake in humans
Wren, A. M., Seal, L. J., Cohen, M. A., Brynes, A. E., Frost, G. S., Murphy, K. G., Dhillo, W. S., Ghatei, M. A., & Bloom, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.12.8111 · Cited by 2,494 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationLeptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus
Cowley, M. A., Smart, J. L., Rubinstein, M., Cerdán, M. G., Diano, S., Horvath, T. L., Cone, R. D., & Low, M. J. (2001) · Nature · doi:10.1038/35078085 · Cited by 2,356 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Gut hormone PYY3-36 physiologically inhibits food intake
Batterham, R. L., Cowley, M. A., Small, C. J., Herzog, H., Cohen, M. A., Dakin, C. L., Wren, A. M., Brynes, A. E., Low, M. J., Ghatei, M. A., et al. (2002) · Nature · doi:10.1038/nature00887 · Cited by 2,351 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationPlasma Ghrelin Levels after Diet-Induced Weight Loss or Gastric Bypass Surgery
Cummings, D. E., Weigle, D. S., Frayo, R. S., Breen, P. A., Ma, M. K., Dellinger, E. P., & Purnell, J. Q. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012908 · Cited by 2,241 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · cited 1×
“Gut hormone PYY(3-36) physiologically inhibits food intake.”
Self-citationObesity in Adulthood and Its Consequences for Life Expectancy: A Life-Table Analysis
Peeters, A., Barendregt, J. J., Willekens, F., Mackenbach, J. P., Mamun, A. A., Bonneux, L., & and for NEDCOM, T. N. E. A. D. C. O. M. R. G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-1-200301070-00008 · Cited by 1,479
Cited by
Items 601–700 of 1,003
Efficiency of the cross‐over design: an empirical estimation
García‐Esteban, R., Benet, M., Arnau, C., & Cobo, E. (2004) · Statistics in Medicine · doi:10.1002/sim.2072 · Cited by 48
Romon, M., Gomila, S., Hincker, P., Soudan, B., & Dallongeville, J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1050 · Cited by 40
Luttikhold, J., de Ruijter, F. M., van Norren, K., Diamant, M., Witkamp, R. F., van Leeuwen, P. A. M., & Vermeulen, M. A. R. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12421 · Cited by 44
Nutrition Rehabilitation in the Intensive Care Unit
Massanet, P. L., Petit, L., Louart, B., Corne, P., Richard, C., & Preiser, J. (2015) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/0148607114567901 · Cited by 43
Campolier, M., Thondre, S., Clegg, M., Shafat, A., Mcintosh, A., & Lightowler, H. J. (2016) · Appetite · doi:10.1016/j.appet.2016.07.027 · Cited by 45
“PYY’s 50 secretion in the distal intestine is stimulated post-prandially and this is related to the caloric and 51 macronutrient content of the meal (Adrian et al., 1985; Batterham et al., 2003).”
Milliken, B. T., Elfers, C., Chepurny, O. G., Chichura, K. S., Sweet, I. R., Borner, T., Hayes, M. R., Jonghe, B. C. D., Holz, G. G., Roth, C. L., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01783 · Cited by 41
Baraboi, E., Michel, C., Smith, P., Thibaudeau, K., Ferguson, A. V., & Richard, D. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07318.x · Cited by 42
“Previous experiments in a number of species have emphasized the role played by PYY in reducing food intake (Batterham et al., 2003; Pittner et al., 2004; Vrang et al., 2006; Chelikani et al., 2007; Parkinson et al., 2008).”
BackgroundWillis, H., Thomas, W. T. B., Eldridge, A. L., Harkness, L., Green, H., & Slavin, J. L. (2010) · Food & Nutrition Research · doi:10.3402/fnr.v54i0.5135 · Cited by 44
Metabolic signals in sleep regulation: recent insights
Basheer, R., & Shukla, C. (2016) · Nature and Science of Sleep · doi:10.2147/nss.s62365 · Cited by 36
“120,121 In a report from human subjects in which the effect of 5 days of reduced sleep was investigated, significant weight gain was observed in spite of changes in the levels of ghrelin, leptin, and peptide YY that signal excess energy stores suggestive of decreased sensitivity to the satiety…”
The role of the endocannabinoid system in the regulation of energy homeostasis
Cota, D., & Woods, S. C. (2005) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000178715.87999.69 · Cited by 40
Hung, C.-C. C., Pirie, F. J., Luan, J., Lank, E., Motala, A. A., Yeo, G. S. H., Keogh, J. M., Wareham, N. J., O’Rahilly, S., & Farooqi, I. S. (2004) · Diabetes · doi:10.2337/diabetes.53.9.2461 · Cited by 39
Ghrelin but Not Peptide YY Is Related to Change in Body Weight and Energy Availability
SCHEID, J. L., DE SOUZA, M. J., LEIDY, H. J., & WILLIAMS, N. I. (2011) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e31821e52ab · Cited by 38
“G hrelin and peptide YY (PYY) are both gastrointestinal peptides; PYY is secreted from the endocrine L cells of the ileum of the intestine (1,2), whereas ghrelin is secreted by distinct endocrine cells of the stomach called X/A-like cells or ghrelin cells (13).”
BackgroundPosovszky, C., & Wabitsch, M. (2014) · Hormone Research in Paediatrics · doi:10.1159/000368898 · Cited by 47
Satiety, but not total PYY, Is increased with continuous and intermittent exercise
Holmstrup, M. E., Fairchild, T. J., Keslacy, S., Weinstock, R. S., & Kanaley, J. A. (2013) · Obesity · doi:10.1002/oby.20335 · Cited by 39
“However, since both PYY1-36 and PYY3-36 are considered physiologically relevant to appetite regulation, particularly over the course of an entire day, the decision was made to measure total PYY (31,32).”
BackgroundMethodInfluentialElmansi, A. M., Awad, M. E., Eisa, N. H., Kondrikov, D., Hussein, K. A., Aguilar‐Perez, A., Herberg, S., Periyasamy‐Thandavan, S., Fulzele, S., Hamrick, M. W., et al. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.005 · Cited by 40
Appetite and obesity: a gastroenterologist's perspective
Camilleri, M., & Grudell, A. (2007) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2006.00864.x · Cited by 43
Στράτης, Χ., Alexandrides, T. K., Vagenas, K., & Kalfarentzos, F. E. (2006) · Obesity Surgery · doi:10.1381/096089206777346772 · Cited by 38
Lenz, A., & Diamond, F. B. (2008) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e3282f43a5b · Cited by 37
Macronutrients and obesity: Revisiting the calories in, calories out framework
Riera‐Crichton, D., & Tefft, N. (2014) · Economics & Human Biology · doi:10.1016/j.ehb.2014.04.002 · Cited by 47
Ghrelin and Peptide YY in Youth: Are There Race-Related Differences?
Bacha, F. F., & Arslanian, S. A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2448 · Cited by 38
Aukan, M. I., Coutinho, S., Pedersen, S. A., Simpson, M. R., & Martins, C. (2023) · Obesity Reviews · doi:10.1111/obr.13531 · Cited by 39
Oral Delivery of the Appetite Suppressing Peptide hPYY(3–36) through the Vitamin B12 Uptake Pathway
Fazen, C. H., Valentin, D., Fairchild, T. J., & Doyle, R. P. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2012547 · Cited by 41
MRI assessment of the postprandial gastrointestinal motility and peptide response in healthy humans
Khalaf, A., Hoad, C. L., Menys, A., Nowak, A., Taylor, S. A., Paparo, S. B., Lingaya, M. R., Falcone, Y., Singh, G., Spiller, R. E., et al. (2017) · Neurogastroenterology & Motility · doi:10.1111/nmo.13182 · Cited by 39
The PYY/Y2R-Deficient Mouse Responds Normally to High-Fat Diet and Gastric Bypass Surgery
Boland, B., Mumphrey, M. B., Hao, Z., Gill, B., Townsend, R. L., Yu, S., Münzberg, H., Morrison, C. D., Trevaskis, J. L., & Berthoud, H.-R. (2019) · Nutrients · doi:10.3390/nu11030585 · Cited by 39
Nonogaki, K. (2007) · Vitamins and hormones · doi:10.1016/s0083-6729(06)77007-8 · Cited by 48
Effect of Honey versus Sucrose on Appetite, Appetite-Regulating Hormones, and Postmeal Thermogenesis
Larson‐Meyer, D. E., Willis, K. S., Willis, L. M., Austin, K. J., Hart, A. M., Breton, A. B., & Alexander, B. M. (2010) · Journal of the American College of Nutrition · doi:10.1080/07315724.2010.10719885 · Cited by 43
“This analysis was based on previous data from our laboratory in healthy postpartum women and assumed that the SD at 60 minutes after meal ingestion (thought to be the postprandial peak [30]) was 12 pg/ml.”
BackgroundMethodClarke, I. J., Backholer, K., & Tilbrook, A. J. (2004) · Endocrinology · doi:10.1210/en.2004-1085 · Cited by 38
Parkinson, J. R. C., Dhillo, W. S., Small, C. J., Chaudhri, O. B., Bewick, G. A., Pritchard, I., Moore, S., Ghatei, M. A., & Bloom, S. R. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00405.2007 · Cited by 38
Self-citationGut: A key player in the pathogenesis of type 2 diabetes?
Muscogiuri, G., Balercia, G., Barrea, L., Cignarelli, A., Giorgino, F., Holst, J. J., Laudisio, D., Orio, F., Tirabassi, G., & Colao, A. (2018) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2016.1252712 · Cited by 37
“PYY seems not to have a direct and significant influence on insulin and glucose levels as demonstrated by studies which have tested the infusion of PYY in healthy subjects (Adrian et al., 1986; Ahren and Larsson, 1996; Batterham et al., 2003).”
BackgroundTorekov, S. S., Larsen, L. H., Glümer, C., Borch-Johnsen, K., Jørgensen, T., Holst, J. J., Madsen, O. D., Hansen, T., & Pedersen, O. (2005) · Diabetes · doi:10.2337/diabetes.54.7.2261 · Cited by 37
Bowels control brain: gut hormones and obesity
Bewick, G. A. (2012) · Biochemia Medica · doi:10.11613/bm.2012.032 · Cited by 36
Enteroendocrine Cells: Metabolic Relays between Microbes and Their Host
Plovier, H., & Cani, P. D. (2017) · Endocrine Development · doi:10.1159/000475736 · Cited by 36
Hypothalamic Integration of the Endocrine Signaling Related to Food Intake
Klockars, A., Levine, A. S., & Olszewski, P. K. (2018) · Current topics in behavioral neurosciences · doi:10.1007/7854_2018_54 · Cited by 39
Treatment strategies for obesity
Wilding, J. P. H. (2007) · Obesity Reviews · doi:10.1111/j.1467-789x.2007.00333.x · Cited by 50
“PYY concentrations are low in obesity, and PYY infusion decreases food intake in lean and obese subjects (37).”
BackgroundCombinations of drugs in the Treatment of Obesity
Halpern, B., Oliveira, E. S. L., Faria, A. M., Halpern, A., Melo, M. E. D., Cercato, C., & Mancini, M. C. (2010) · Pharmaceuticals · doi:10.3390/ph3082398 · Cited by 35
“Peptide YY (PYY 3-36) is gut hormone which is also secreted after a meal [37,59].”
BackgroundGetting to the bottom of feeding behaviour: who’s on top?
Cameron, J., & Doucet, É. (2007) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/h06-072 · Cited by 36
Obesity: New Perspectives and Pharmacotherapies
Palamara, K., Mogul, H. R., Peterson, S. J., & Frishman, W. H. (2006) · Cardiology in Review · doi:10.1097/01.crd.0000233903.57946.fd · Cited by 39
Nguyen, N. Q., Fraser, R. J., Chapman, M. J., Bryant, L. K., Wishart, J. M., Holloway, R. H., & Horowitz, M. (2006) · Critical Care · doi:10.1186/cc5127 · Cited by 36
Physiology of Weight Loss Surgery
Park, C. W., & Torquati, A. (2011) · Surgical Clinics of North America · doi:10.1016/j.suc.2011.08.009 · Cited by 44
“In addition, this study also showed that PYY infusion caused a decrease in ghrelin levels, suggesting an interaction between appetite suppression and stimulation along the enteroendocrine axis.(48) Obese individuals have been shown to produce lower baseline levels of PYY compared with those who are lean and of normal…”
BackgroundPathophysiology of Obesity: Why Surgery Remains the Most Effective Treatment
Waseem, T., Mogensen, K. M., Lautz, D. B., & Robinson, M. K. (2007) · Obesity Surgery · doi:10.1007/s11695-007-9220-1 · Cited by 45
Mechanisms of Weight Loss after Gastric Bypass and Gastric Banding
Bueter, M., Ashrafian, H., & le Roux, C. W. (2009) · Obesity Facts · doi:10.1159/000232383 · Cited by 35
Emerging therapies in the treatment of ‘diabesity’: beyond GLP-1
Tharakan, G., Tan, T., & Bloom, S. R. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.10.003 · Cited by 39
Self-citationGastrointestinal hormones and their role in obesity
Choudhury, S. M., Tan, T. M., & Bloom, S. R. (2016) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000216 · Cited by 35
Self-citationLarsen, P. S., Donges, C. E., Guelfi, K. J., Smith, G. C., Adams, D. R., & Duffield, R. (2017) · International Journal of Sport Nutrition and Exercise Metabolism · doi:10.1123/ijsnem.2017-0144 · Cited by 44
Mancuso, C., Izquierdo, A. M., Slattery, M. J., Becker, K. R., Plessow, F., Thomas, J. J., Eddy, K. T., Lawson, E. A., & Misra, M. (2019) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2019.104556 · Cited by 44
The Design of a GLP‐1/PYY Dual Acting Agonist
Østergaard, S., Paulsson, J. F., Gerstenberg, M. K., & Wulff, B. S. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202016464 · Cited by 38
The nutritional control of ghrelin secretion in humans
Prodam, F., Me, E., Riganti, F., Gramaglia, E., Bellone, S., Baldelli, R., Rapa, A., van der Lely, A. J., Bona, G., Ghigo, E., et al. (2006) · European Journal of Nutrition · doi:10.1007/s00394-006-0613-z · Cited by 35
“Specifically, the involvement of several factors has been described, including the central activation of the cephalic phase of appetite [7, 8], the caloric content of the ingested meals [9, 10], the glycemic content of nutrients as well as the insulin responses to food intake [5, 11‐13], and even several neuro-hormona…”
BackgroundGhrelin in Chronic Kidney Disease
Cheung, W. W., & MAK, R. H. K. (2010) · International Journal of Peptides · doi:10.1155/2010/567343 · Cited by 37
Expression of peptide YY in human brain and pituitary tissues
Morimoto, R., Satoh, F., Murakami, O., Totsune, K., Saruta, M., SUZUKI, T. A., Sasano, H., Ito, S., & Takahashi, K. (2008) · Nutrition · doi:10.1016/j.nut.2008.06.011 · Cited by 35
Cholinergic Regulation of Ghrelin and Peptide YY Release May Be Impaired in Obesity
Maier, C., Riedl, M., Vila, G., Nowotny, P., Wolzt, M., Clodi, M., Ludvik, B. H., & Luger, A. (2008) · Diabetes · doi:10.2337/db07-0758 · Cited by 42
“PYY levels are reported to be reduced (17) or unaltered (20) in obesity and increased in anorexia nervosa (20).”
BackgroundRoque, M. I. V., Camilleri, M., Clark, M. M., TePoel, D. A., Jensen, M. D., Graszer, K. M., Kalsy, S. A., Burton, D. D., Baxter, K. L., & Zinsmeister, A. R. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.02.037 · Cited by 35
A PYY Q62P variant linked to human obesity
Ahituv, N., Kavaslar, N., Schackwitz, W., Ustaszewska, A., Collier, J. M., Hébert, S., Doelle, H., Dent, R., Pennacchio, L. A., & McPherson, R. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi455 · Cited by 36
“In rodents, intravenous administration of PYY3–36 led to a reduction in food intake (6,7,11) and in both obese and lean human subjects, PYY3–36 infusion markedly decreased food intake (8).”
BackgroundGastrointestinal peptides and bone health
Wong, I. P. L., Baldock, P. A. J., & Herzog, H. (2010) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3283344a05 · Cited by 39
Siddiq, A., Gueorguiev, M., Samson, C., Herçberg, S., Heude, B., Lévy‐Marchal, C., Jouret, B., Weill, J., Meyre, D., Walley, A. J., et al. (2007) · Diabetologia · doi:10.1007/s00125-006-0555-2 · Cited by 41
“Over the last few years much emphasis has been placed on the role of PYY, PPY and NPY2R in relation to obesity [6, 12, 16, 22, 28, 33] in both humans and animal models.”
BackgroundDistribution and Stimulus Secretion Coupling of Enteroendocrine Cells along the Intestinal Tract
Adriaenssens, A. E., Reimann, F., & Gribble, F. M. (2018) · Comprehensive physiology · doi:10.1002/cphy.c170047 · Cited by 41
Cracking the combination: Gut hormones for the treatment of obesity and diabetes
Alexiadou, K., Anyiam, O., & Tan, T. (2019) · Journal of Neuroendocrinology · doi:10.1111/jne.12664 · Cited by 34
Tan, T. M. ‐., Minnion, J., Khoo, B., Ball, L., Malviya, R., Day, E., Fiorentino, F., Brindley, C., Bush, J., & Bloom, S. R. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14358 · Cited by 34
Self-citationMechanisms of bariatric surgery for weight loss and diabetes remission
Yin, M., Wang, Y., Han, M., Liang, R., Li, S., Wang, G., & Gang, X. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13443 · Cited by 46
“80 Meanwhile, attenuated postprandial PYY secretion was observed in the early stages of T2D development.”
Liu, H., Xiao, H., Lin, S., Zhou, H., Cheng, Y., Xie, B., & Xu, D. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1372399 · Cited by 40
Metabolic surgery—principles and current concepts
Gass, M., Beglinger, C., & Peterli, R. (2011) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-011-0834-3 · Cited by 43
Ginseng Panaxoside Rb1 Reduces Body Weight in Diet-Induced Obese Mice
Lin, N., Cai, D.-L., Jin, D., Chen, Y., & Shi, J. (2013) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-013-9688-3 · Cited by 34
“PYY3–36-NPY axis is an important neuroendocrine pathway regulating food intake and in turn, energy balance [41–44].”
BackgroundHu, T., Yang, Z., & Li, M. D. (2018) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-018-9800-y · Cited by 34
Protein PYY and Its Role in Metabolism
Price, S. L., & Bloom, S. R. (2014) · Frontiers of hormone research · doi:10.1159/000358343 · Cited by 36
Self-citationShi, Y., Zhou, L., Lau, J., Zhang, H. E., Yagi, M., Kanzler, I., Sainsbury, A., Herzog, H., & Lin, S. (2013) · Obesity · doi:10.1002/oby.20534 · Cited by 40
“It appears that obese individuals have a deficiency in circulating PYY (8,9), indicating a potential role for PYY in the development of obesity.”
BackgroundLin, N., Li, Y., Tang, L., Shi, J., & Chen, Y. (2013) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201200695 · Cited by 40
“PYY3–36-NPY axis is an important neuroendocrine pathway regulating food intake and in turn, energy balance [6,9,10].”
BackgroundSerum peptide YY in response to short-term overfeeding in young men
Cahill, F., Shea, J. L., Randell, E. W., Vasdev, S., & Sun, G. (2011) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.003624 · Cited by 45
Pais, R., Rievaj, J., Meek, C. L., Costa, G. D., Jayamaha, S., Alexander, R. T., Reimann, F. M., & Gribble, F. M. (2016) · The Journal of Physiology · doi:10.1113/jp272053 · Cited by 37
“Age was significantly higher and BMI significantly lower in the low osmo group compared to the high osmo group.”
ResultInfluentialGarcía, G. M., Agüı́, L., Yáñez‐Sedeño, P., & Pingarrón, J. M. (2016) · Electrochimica Acta · doi:10.1016/j.electacta.2016.03.140 · Cited by 34
The Temporal Sequence of Gut Peptide–CNS Interactions Tracked In Vivo by Magnetic Resonance Imaging
Kuo, Y., Parkinson, J. R. C., Chaudhri, O. B., Herlihy, A. H., So, P., Dhillo, W. S., Small, C. J., Bloom, S. R., & Bell, J. D. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.2391-07.2007 · Cited by 34
“In contrast to ghrelin, PYY3–36 inhibits food intake in rodents and humans (Batterham et al., 2002, 2003).”
BackgroundSelf-citationNovel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Impact of Duodenal-Jejunal Exclusion on Satiety Hormones
de Jonge, C., Rensen, S. S., Verdam, F. J., Vincent, R. P., Bloom, S. R., Buurman, W. A., le Roux, C. W., Bouvy, N. D., & Greve, J. W. M. (2015) · Obesity Surgery · doi:10.1007/s11695-015-1889-y · Cited by 37
Self-citationGastric Emptying and Postprandial PYY Response After Biliopancreatic Diversion with Duodenal Switch
Hedberg, J., Hedenström, H., Karlsson, F. A., Engström, B. E., & Sundbom, M. (2010) · Obesity Surgery · doi:10.1007/s11695-010-0288-7 · Cited by 38
“In contrast, non-operated obese subjects have low [ 40 ] or normal [22, 41, 42] levels of PYY.”
BackgroundAstbury, N. M., Taylor, M. A., French, S., & Macdonald, I. A. (2014) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.113.075978 · Cited by 36
Obestatin and ghrelin in obese and in pregnant women
Fontenot, E., DeVente, J., & Seidel, E. R. (2007) · Peptides · doi:10.1016/j.peptides.2007.08.005 · Cited by 35
Tsilchorozidou, T., Batterham, R. L., & Conway, G. S. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03285.x · Cited by 33
Self-citationForssten, S. D., Korczyńska, M. Z., Zwijsen, R. M. L., Noordman, W. H., Madetoja, M., & Ouwehand, A. C. (2013) · Appetite · doi:10.1016/j.appet.2013.06.093 · Cited by 37
Lumb, K. J., DeCarr, L. B., Milardo, L. F., Mays, M. R., Buckholz, T. M., Fisk, S. E., Pellegrino, C. M., Ortiz, A. A., & Mahle, C. D. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061454v · Cited by 33
Hage, M. P., Safadi, B. Y., Salti, I., & Nasrallah, M. (2012) · ISRN Endocrinology · doi:10.5402/2012/504756 · Cited by 36
“PYY(3–36) infusion also decreased ghrelin levels [83].”
BackgroundBoza, C., Gagner, M., Devaud, N. A., Escalona, A., Muñoz, R., & Gandarillas, M. (2008) · Surgical Endoscopy · doi:10.1007/s00464-007-9685-y · Cited by 33
“inhibits food intake up to 12 hours after injection [14], suggesting an intermediate time-interval effect between quickly acting peptides that control individual meals (CCK, ghrelin) and more slowly working hormones that control body weight (leptin, insulin).”
BackgroundHensrud, D. D. (2004) · Current Opinion in Gastroenterology · doi:10.1097/00001574-200403000-00012 · Cited by 38
Body Fat Regulation: Is It a Result of a Simple Energy Balance or a High Fat Intake?
Pereira-Lancha, L. O., Coelho, D., de Campos‐Ferraz, P. L., & Lancha, A. H. (2010) · Journal of the American College of Nutrition · doi:10.1080/07315724.2010.10719850 · Cited by 38
“However, it has been demonstrated that in obese subjects, PYY levels are lower than in normal individuals, so that this satiety mechanism is less efficient in the former case [25].”
BackgroundImpact of Gastric Bypass Surgery on Gut Hormones and Glucose Homeostasis in Type 2 Diabetes
Näslund, E. B., & Kral, J. G. (2006) · Diabetes · doi:10.2337/db06-s012 · Cited by 36
“In analogy to GLP-1, postprandial plasma PYY concentrations have recently been shown to be lower in obese than lean subjects (71), which supports the proposal that PYY (3-36) is a mediator of satiety.”
BackgroundResultRohde, U., Sonne, D. P., Christensen, M., Hansen, M., Brønden, A., Toräng, S., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1133 · Cited by 35
“(1) PLA saline 27 (25; 41) 6340 (5259; 6781)*(2,4) 23 (19; 31)*(2,4) 50 (20; 60) (2) PLA CCK 29 (21; 45) 3778 (3109; 4836)*(1,3) 2 (1; 4)*(1,3) 40 (40; 60) (3) MET saline 38 (29; 50) 6617 (6065; 8103)*(2,4) 29 (20; 41)*(2,4) 20 (20; 68) (4) MET CCK 37 (21; 50) 4307 (3094; 5414)*(1,3) 3 (1; 8)*(1,3) 50 (40; 60) rmANOVA…”
BackgroundRockwood, S., Mason, D., Lord, R., Lamar, P. C., Prozialeck, W. C., & Al‐Nakkash, L. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s216312 · Cited by 35
“21 Moreover, administration of gut hormones such as PYY and PP can lead to reduced food intake and weight loss.”
BackgroundRahardjo, G., Huang, X., Tan, Y. Y., & Deng, C. (2007) · Endocrinology · doi:10.1210/en.2007-0107 · Cited by 36
“This attenuated response of PYY release in obese populations (34) has been shown to cause an insufficient inhibitory effect on feeding (35, 36).”
BackgroundGut Hormones Ghrelin, PYY, and GLP-1 in the Regulation of Energy, Balance, and Metabolism
Pérez–Tilve, D., Nogueiras, R., Mallo, F., Benoit, S. C., & Tschoep, M. H. (2006) · Endocrine · doi:10.1385/endo:29:1:61 · Cited by 42
King, J. A., Garnham, J. O., Jackson, A. P., Kelly, B. M., Xenophontos, S., & Nimmo, M. A. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.12.050 · Cited by 40
“PYY is an anorectic peptide secreted primarily by the distal intestine in response to nutrient intake [9,35].”
Translational studies on PYY as a novel target in obesity
Zac‐Varghese, S., Silva, A. D., & Bloom, S. R. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.10.001 · Cited by 37
Self-citationCNS-targeting pharmacological interventions for the metabolic syndrome
Stemmer, K., Müller, T. D., DiMarchi, R. D., Pfluger, P. T., & Tschöp, M. H. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129195 · Cited by 36
“However, discrepant results in rodents (106, 107) and high levels of nausea in humans (108) impeded further clinical developments.”
ResultJones, E. S., Nunn, N., Chambers, A. P., Østergaard, S., Wulff, B. S., & Luckman, S. M. (2019) · Endocrinology · doi:10.1210/en.2019-00100 · Cited by 33
Russell, M., & Misra, M. (2010) · Medicine and sport science/Medicine and sport · doi:10.1159/000321975 · Cited by 39
“PYY levels are low in obesity (62) and elevated in low energy availability states such as anorexia nervosa (34).”
BackgroundLeptin, adiponectin, and ghrelin dysregulation in chronic kidney disease
Guebre‐Egziabher, F., Bernhard, J., Geelen, G., Malvoisin, E., Hadj‐Aïssa, A., & Fouque, D. P. (2005) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2004.09.015 · Cited by 32
Intestinal microbiota and overweight
Lyra, A., Lahtinen, S., Tiihonen, K., & Ouwehand, A. (2010) · Beneficial Microbes · doi:10.3920/bm2010.0030 · Cited by 32
Combination therapy for obesity and metabolic disease
Gadde, K. M., & Allison, D. B. (2009) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e3283304f90 · Cited by 32
Role of Gut Hormones in Obesity
Jayasena, C. N., & Bloom, S. R. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.07.001 · Cited by 39
Self-citationRigamonti, A. E., Agosti, F., Compri, E., Giunta, M., Marazzi, N., Müller, E. E., Cella, S. G., & Sartório, A. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0867 · Cited by 38
Bonačić, K., Campoverde, C., Gómez-Arbonés, J., Gisbert, E., Estévez, A., & Morais, S. (2016) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2016.02.002 · Cited by 36
Torekov, S. S., Larsen, L. H., Andersen, G., Albrechtsen, A., Glümer, C., Borch‐Johnsen, K., Jørgensen, T., Hansen, T. F., & Pedersen, O. B. (2006) · Diabetologia · doi:10.1007/s00125-006-0425-y · Cited by 32
“Interestingly, obese subjects have lower plasma PYY levels and a relatively smaller increase in circulating PYY levels after a meal compared with lean subjects [7], suggesting that gene variants in PYY may alter the level of Diabetologia (2006) 49:2653–2658”
BackgroundGut Hormones as Potential New Targets for Appetite Regulation and the Treatment of Obesity
Field, B. C. T., Wren, A., Cooke, D., & Bloom, S. R. (2008) · Drugs · doi:10.2165/00003495-200868020-00002 · Cited by 38
Self-citationNeuropeptides in Eating Disorders
Jimerson, D. C., & Wolfe, B. E. (2004) · CNS Spectrums · doi:10.1017/s1092852900009603 · Cited by 32
Metadata
- Authors
- Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R.
- Affiliations
- Imperial College London (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-09-04
- Volume
- 349
- Issue
- 10
- Pages
- 941-948
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2170277935
- Cited by
- 1,604
- References
- 27
- Citations by year
- 2026: 31 · 2025: 28 · 2024: 31 · 2023: 29 · 2022: 33 · 2021: 54 · 2020: 40 · 2019: 63 · 2018: 44 · 2017: 61 · 2016: 61 · 2015: 60 · 2014: 78 · 2013: 83 · 2012: 89
- FWCI
- 38.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- PYY3-36, peptide YY, obesity, dietary intake, appetite, ghrelin, leptin resistance, gastrointestinal hormones, hypothalamic regulation of appetite, body mass index, energy intake
- MeSH terms
- Appetite, Double-Blind Method, Eating, Female, Humans, Insulin, Male, Obesity, Peptide Fragments, Cross-Over Studies, Peptide YY, Leptin, Peptide Hormones, Ghrelin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.